Through fusion with glycosylphosphatidylinositol anchors, anti-epidermal growth factor receptor (EGFR) nanobodies were strongly enriched in EVs and greatly improved the capacity of targeting tumor cells (Kooijmans et al., 2016). This evidence concerns the gene EGFR and neoplasm.